Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05870761 · ClinicalTrials.gov registry record · Phase 2
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
A Phase 2 study of Recurrent Endometrial Serous Adenocarcinoma, sponsored by Casey Cosgrove.
- Active
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05870761 is a Phase 2 study of Recurrent Endometrial Serous Adenocarcinoma that is active but no longer recruiting, run by Casey Cosgrove. The registered enrollment target is 8 participants, below the 43-participant average among 3 other Recurrent Endometrial Serous Adenocarcinoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05870761, a Phase 2 study of Recurrent Endometrial Serous Adenocarcinoma, is active but no longer recruiting, sponsored by Casey Cosgrove.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent). Niraparib belongs to a class of drugs called PARP inhibitors that prevent cancer cells from growing. Dostarlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Dostarlimab belongs to a class of drugs called PD-1 inhibitors that uses the patient's own immune system to treat cancer (immuno-therapy). Giving niraparib and dostarlimab may work better in treating patients with uterine serous carcinoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- DRUG Niraparib
- BIOLOGICAL Dostarlimab
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-10-17 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05870761
The ClinicalTrials.gov registry entry for NCT05870761 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 3 other Recurrent Endometrial Serous Adenocarcinoma trials with a reported enrollment target (81% lower). The listed sponsor is Casey Cosgrove, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Endometrial Serous Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05870761 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05870761 about?
NCT05870761 is a clinical study titled "Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma". This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent). Niraparib belongs to a class of drugs called PARP inhibitors that prevent ca...
What is the current status of trial NCT05870761?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-10-17. Estimated completion is 2025-12-31.
What conditions does trial NCT05870761 study?
This clinical trial studies the following conditions: Recurrent Endometrial Serous Adenocarcinoma.
What interventions are being tested in trial NCT05870761?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Niraparib (DRUG), Dostarlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05870761?
This trial is sponsored by Casey Cosgrove, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05870761 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Endometrial Serous Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.